Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | REN | P00797 | 5/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041288 | 1.00 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23302438 | 1.00 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11095014 | 1.00 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28525267 | 0.93 | REN (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28525268 | 0.93 | REN (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28525265 | 0.93 | REN (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22393402 | 0.92 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17899496 | 0.91 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11089707 | 0.90 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20506597 | 0.90 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023178130-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20220409600-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11389438-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-112062768-B | Micromolecule with Aurora kinase degradation activity and preparation method and application thereof | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2021-08-31 | — | — | CN | disclosed |
| WO-2021086069-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2021-05-06 | — | — | WO | disclosed |
| CN-112125951-A | Impurities in ubenimex bulk drug and preparation method thereof | 深圳万乐药业有限公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-112062768-A | Micromolecule with Aurora kinase degradation activity and preparation method and application thereof | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2020-12-11 | — | — | CN | disclosed |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | CHDI FOUNDATION, INC. | 2020-09-03 | — | — | US | disclosed |
| WO-2013026942-A1 | TUBULIN BINDING AGENTS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | PSEN1 212/4885PSEN2 95/4885APH1B 445/4885 |
| US-11389438-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | PSEN1 212/4885PSEN2 95/4885APH1B 445/4885 |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | HTT, HYPK, UBQLN2 | PSEN1 212/4885PSEN2 95/4885APH1B 445/4885 |
| US-20220409600-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | HTT, HYPK, UBQLN2 | PSEN1 212/4885PSEN2 95/4885APH1B 445/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | PSEN1 20/4885PSEN2 66/4885APH1B 440/4885 |
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, CUL1, SOS2 | PSEN1 266/4885PSEN2 742/4885APH1B 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.